Research & Development

Amprologix wins DHSC backing for new antibiotic

Frontier IP, a specialist in commercialising university intellectual property, today announces portfolio company Amprologix (the "Company") has won a contract worth £1.2 million funded by the UK Department for Health and Social Care to accelerate development and scale up its lead antibiotic candidate to tackle antimicrobial resistant MRSA and related superbugs.

IQVIA to deliver clinical solutions for small biotech and biopharma firms

IQVIA has announced the launch of IQVIA Biotech and its new approach to delivering tailored clinical and commercial solutions for small biotech and biopharma companies.

Caelum signs deal with Alexion to advance CAEL-101 development

Fortress Biotech, a biopharmaceutical company focused on acquiring, developing and commercializing pharmaceutical and biotechnology products, announced that Caelum Biosciences has signed a strategic agreement with Alexion Pharmaceuticals to advance the development of CAEL-101 for light chain (AL) amyloidosis.

Janssen, MeiraGTx sign $440m deal to develop gene therapy programs for IRDs

Janssen Pharmaceuticals and MeiraGTx have signed an agreement worth $440m to develop gene therapy programs for inherited retinal diseases (IRDs).

Dewpoint Therapeutics launches with $60m Series A to advance proprietary platform for drugging condensates

Dewpoint Therapeutics, a company translating the emerging area of biomolecular condensates into drug discovery, launched today with a $60 million Series A.

Lyndra Therapeutics raises $55m in Series B financing

Lyndra Therapeutics, which is moving toward making daily pills a thing of the past, has raised $55 million in Series B financing, funds it will use for Phase II clinical trials, expansion of its Phase I pipeline and manufacturing scale-up.

EIB to lend €100m to Orion for pharmaceutical research and development

Finnish pharmaceutical firm Orion Oyj has signed a loan agreement of €100m with the European Investment Bank in Espoo.

BridgeBio Pharma raises $299.2m in financing round

BridgeBio Pharma, a clinical-stage biopharmaceutical firm focused on the development of medicines for genetic diseases, has secured $299.2m funds to advanced its existing drug research and development programs.

GSK closes acquisition of Tesaro for $5.1bn

British drugmaker GlaxoSmithKline (GSK) has completed the acquisition of the US-based oncology-focused biopharmaceutical firm Tesaro for $5.1bn (£4bn).